Vir Biotechnology price target raised to $13 from $12 at JPMorgan

JPMorgan analyst Eric Joseph raised the firm’s price target on Vir Biotechnology to $13 from $12 and keeps a Neutral rating on the shares. The firm said that data presented from the company’s phase 2 SOLSTICE trial at EASL are supportive of the treatment regimen in hepatitis D, although it still looks for further regulatory clarity and the phase 3 study design to gain more confidence on path to approval.